Dextenza 0.4Mg Ophthalmic Insert + Topical prednisolone acetate
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cataract
Conditions
Cataract
Trial Timeline
Aug 23, 2021 → Oct 1, 2022
NCT ID
NCT05023304About Dextenza 0.4Mg Ophthalmic Insert + Topical prednisolone acetate
Dextenza 0.4Mg Ophthalmic Insert + Topical prednisolone acetate is a approved stage product being developed by Ocular Therapeutix for Cataract. The current trial status is completed. This product is registered under clinical trial identifier NCT05023304. Target conditions include Cataract.
What happened to similar drugs?
9 of 19 similar drugs in Cataract were approved
Approved (9) Terminated (3) Active (8)
✅Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Ocular TherapeutixApproved
✅Dextenza 0.4mg intracanalicular Insert + Durezol 0.05% Ophthalmic EmulsionOcular TherapeutixApproved
✅Dexycu + Standard of Care post operative eye drops (steroid, antibiotic, NSAID)EyePoint PharmaceuticalsApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05023304 | Approved | Completed |
Competing Products
20 competing products in Cataract